Key facts
- This page summarizes Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s Form 4 filing for NATURES SUNSHINE PRODUCTS INC (NATR).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 27 Jun 2025, 16:27.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. - 27 Jun 2025 Form 4 Insider Report for NATURES SUNSHINE PRODUCTS INC (NATR)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- NATR
- Reported as of
- 27 Jun 2025
- Net transaction value
- -$32,713,796
- SEC form
- 4
- Accepted by SEC
- 27 Jun 2025, 16:27:23 UTC
- Prior SEC filing
- 17 Oct 2024
- Source filing
- View source filing
- Reporting owner signature
- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. By: /s/ Yuqing Chen, Chairman
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. filed Form 4 for NATURES SUNSHINE PRODUCTS INC (NATR) on 27 Jun 2025.
Change
- Previous filing in this sequence was filed on 17 Oct 2024.
- Current net transaction value: -$32,713,796.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (2)
CIK 0001615258
Primary reporting owner
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- Relationship
- 10%+ Owner
- Address
- BUILDING A,, NO. 1289 YISHAN ROAD, SHANGHAI, CHINA
- Signature
- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. By: /s/ Yuqing Chen, Chairman
- Signature date
- 27 Jun 2025
CIK 0002071437
Fosun Pharma USA Inc.
- Relationship
- 10%+ Owner
- Address
- 104 CARNEGIE CENTER DRIVE, SUITE 204, PRINCETON
- Signature
- Fosun Pharma USA Inc. By: /s/ Yuqing Wang, Chief Financial Officer
- Signature date
- 27 Jun 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NATR
transaction
Common Stock
Sale
- Transaction value
- $32,713,796
- Shares
- -2,854,607
- Change %
- -100%
- Price
- $11.46
- Shares after
- 0
- Date
- 27 Jun 2025
- Ownership
- by Fosun Pharma USA Inc.
- Footnotes
- F1, F2
NATR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 64,167
- Date
- 27 Jun 2025
- Ownership
- by Fosun Industrial Co., Limited
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
The shares were sold pursuant to that certain Underwriting Agreement. dated June 25, 2025, among Fosun Pharma USA Inc., the Issuer, and the underwriter party thereto.
Footnote F2
Fosun Pharma USA Inc. is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Footnote F3
Fosun Industrial Co., Limited is a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.